Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrizia Beccaglia

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Recenti Progressi in Medicina|December 20, 2002
[Anemia induced by solid tumor chemotherapy]Roberto Stasi, Luca Abriani, Patrizia Beccaglia, et al.
Cancer|October 30, 2003
Cancer-related fatigue: evolving concepts in evaluation and treatmentRoberto Stasi, Luca Abriani, Patrizia Beccaglia, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2004
A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancerOttavio Ariganello, Andrea Mancuso, Michele Di Molfetta, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Disability weights for castration-resistant prostate cancer: an empirical investigationLudovica Borsoi, Oriana Ciani, Rocco De Vivo, et al.
The Oncologist|July 22, 2004
Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapyEnrico Cortesi, Andrea Mancuso, Adolfo De Pasquale Ceratti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 14, 2007
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weeklyGiacomo Cartenì, Laura Giannetta, Giovanni Ucci, et al.
Critical Reviews in Oncology/Hematology|September 9, 2008
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patientsFabio Puglisi, Laura Deroma, Stefania Russo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2007
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growthRoberto Bianchi, Alessandra Gilardini, Virginia Rodriguez-Menendez, et al.
Journal of Bone Oncology|January 11, 2021
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDEDaniele Santini, Saverio Cinieri, Donatello Gasparro, et al.
Therapeutic Advances in Medical Oncology|November 16, 2020
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude studyGiuseppe Procopio, Vincenzo Emanuele Chiuri, Monica Giordano, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Recenti Progressi in Medicina|December 20, 2002
[Anemia induced by solid tumor chemotherapy]Roberto Stasi, Luca Abriani, Patrizia Beccaglia, et al.
Cancer|October 30, 2003
Cancer-related fatigue: evolving concepts in evaluation and treatmentRoberto Stasi, Luca Abriani, Patrizia Beccaglia, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2004
A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancerOttavio Ariganello, Andrea Mancuso, Michele Di Molfetta, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Disability weights for castration-resistant prostate cancer: an empirical investigationLudovica Borsoi, Oriana Ciani, Rocco De Vivo, et al.
The Oncologist|July 22, 2004
Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapyEnrico Cortesi, Andrea Mancuso, Adolfo De Pasquale Ceratti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 14, 2007
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weeklyGiacomo Cartenì, Laura Giannetta, Giovanni Ucci, et al.
Critical Reviews in Oncology/Hematology|September 9, 2008
Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patientsFabio Puglisi, Laura Deroma, Stefania Russo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2007
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growthRoberto Bianchi, Alessandra Gilardini, Virginia Rodriguez-Menendez, et al.
Journal of Bone Oncology|January 11, 2021
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDEDaniele Santini, Saverio Cinieri, Donatello Gasparro, et al.
Therapeutic Advances in Medical Oncology|November 16, 2020
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude studyGiuseppe Procopio, Vincenzo Emanuele Chiuri, Monica Giordano, et al.
Pageof 2